Eine Kamera ist auf eine reflektierende Glasscheibe gerichtet.
© DZIF

News

All current DZIF news can be found here.

Electron micrograph of two H. pylori cells in yellow binding to human gastric epithelial cells (stained red below).
© Max von Pettenkofer-Institut der LMU/Rainer Haas

Targeting Helicobacter: nipping stomach cancer in the bud

The pathogen Helicobacter pylori, which is responsible for highly prevalent diseases such as gastric ulcers or cancer, has a weak spot that could be used to produce new drugs. This was discovered by a

The background shows an abstract wave-like light to dark green structure. At the top left of the picture, a segment of an oval can be seen, on which the logo and the subtitle of the project can be seen: eWHORM, Eliminating Worm Infections in Sub-Saharan Africa. The "e" of the logo is formed by a green worm (filaria) in the shape of an "e".
© eWHORM

Launch of the EU-funded project eWHORM – enabling the WHO Road Map: Eliminate worm infections in Sub-Saharan Africa

African and European partners join forces to enable the World Health Organisation’s (WHO) “Road Map for Neglected Tropical Diseases” (NTDs) and reduce the burden of disease associated with worm

The company logo with the words EBViously on top of a schematic virus particle is placed on a background of blue coloured cells and several green coloured virus particles.
© CDC/Dr. Paul M Feorino; DZIF/EBViously

DZIF-project-derived start-up “EBViously“ announces first details of its EBV vaccine candidate

EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective

Portray of Prof Rolf Hilgenfeld, Universität zu Lübeck
© Universität zu Lübeck/Thomas Berg

Carl-Hermann-Medal awarded to Rolf Hilgenfeld

The German Society for Crystallography has awarded the Carl-Hermann-Medal to the biochemist Prof. Rolf Hilgenfeld. The award honours the scientific life of outstanding research personalities in the

Schematic representation in 3D of the transcription factor Rv0678. Some spiral amino acid chains are highlighted in purple or gold.
© CC BY 4.0/Sonnenkalb, L. et al.

Identifying and combating new antibiotic resistance in tuberculosis early on

The antibiotic Bedaquiline (BDQ) was approved in 2014 specifically for the treatment of multidrug-resistant (MDR) tuberculosis (TB) and has since been an important component of successful MDR TB

Female doctor in consultation with a female and a male person
© Andreypopov/Dreamstime.com

German Centers for Health Research support declaration on patient participation of the Health Research Forum

Patients can participate in medical research as active partners. Researchers should consider their needs and their unique expertise in the research process, as it is a valuable resource. The Health

Andreas Dräger and his team
© Uni Tübingen

Preparing for the next pandemic: Targeted computer modelling to accelerate antiviral drug development

Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF

Blocking of cell wall formation by antibiotics stops bacterial cell division

We still do not understand exactly how antibiotics kill bacteria. However, this understanding is necessary if we want to develop new antibiotics. And that is precisely what is urgently needed, because

Fünf gezeichnete Personen (Ärztinnen, Wissenschaftler und Patient:innen) auf rotem Hintergrund, mit hoffnungsvollen Gesichtsausdrücken
© WHO

World Tuberculosis Day 2023: Yes! We can end TB!

According to the World Health Organisation (WHO), approximately 1.5 million people die each year from tuberculosis (TB), a disease of the lungs caused by Mycobacterium tuberculosis. People with a

Shown on a black background are about 12 nuclei of lung cells in purple and a green-stained oval SARS-CoV-2 virus particle.
© HZI/Ulfert Rand

Bacterial weapons against viral diseases

The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available